Skip to search formSkip to main contentSkip to account menu

NSC 332488

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

anaxirone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1992
Review
1992
Pharmacology of High-Dose 1,2,4-Triglycidylurazol in Preparative Regimens for Bone Marrow Transplantation: Preclinical Evaluation and First Clinical Results
The racematic compound a/β-1,2,4-triglycidylurazol (TGU; NSC 332488) a triepoxide with alkylating properties, has a broad… 
1986
1986
A clinical and pharmacokinetic phase I study of 1,2,4-triglycidylurazol (TGU, NSC 332488).
1986
1986
Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent--a phase II study of the EORTC early clinical trials group.
1986
1986
Preclinical and clinical study of anaxirone using an HPLC assay (NSC 332488; TGU)
1985
1985
Phase I trial of 1,2,4-triglycidylurazol (TGU, NSC 332488): a new triepoxide cytostatic agent.
1984
1984
alpha-/beta-Triglycidyl-urazol (TGU, NSC 332488, I.N.N.: ANAXIRONE): a new chemotherapeutic agent.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)